Short QT Interval Syndromes

ByL. Brent Mitchell, MD, Libin Cardiovascular Institute of Alberta, University of Calgary
Reviewed/Revised Jun 2024
View Patient Education

The short QT interval syndromes (SQTS) are extremely rare congenital or very rarely acquired disorders of cardiac ion channel function or regulation that shorten ventricular myocyte action potential duration as reflected by shortening of the rate-corrected QT interval on the ECG.

(See also Overview of Arrhythmias and Overview of Channelopathies.)

The cardiac ion channel dysfunction may involve

  • Gain of function of repolarizing potassium current channels

  • Loss of function of depolarizing sodium or depolarizing calcium current channels

  • Loss of function of the Cl-/HCO3- exchanger

Note that the changes in gain of function of repolarizing potassium current channels or loss of function of depolarizing sodium or depolarizing calcium current channels are the opposite of those occurring in long QT interval syndrome.

The resultant shortening of the action potential duration is most marked in the ventricular epicardium and may lead to polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) often leading to sudden death. The likelihood of ventricular tachyarrhythmias increases with the degree of rate-corrected QT interval (QTc) shortening. Some patients with SQTS are also prone to atrial fibrillation. An overlap syndrome with the early repolarization syndrome has been reported.

Short QT interval syndromes are classified based on the specific gene that has mutated. The most common abnormal genes include KCNH2, KCNQ1, KCNJ2, and SLC4A3.

Patients are asymptomatic unless atrial fibrillation or VT/VF occurs, which may cause palpitations, near syncope, syncope, or cardiac arrest.

Diagnosis of Short QT Interval Syndromes

  • Specific clinical and electrocardiographic criteria

  • Genetic testing

  • Screening of first-degree family members

Diagnosis should be considered in patients with unexplained cardiac arrest or syncope or a family history of such when the affected people do not have structural heart disease. It should also be considered in people who are discovered to have a short QT interval when ECG is done for other reasons.

Diagnosis is by ECG showing shortening of the QTc. The degree of shortening of the QTc required is debated but ranges from < 0.30 second to 0.36 second; the longer durations may be more appropriate when patients or family members have a known mutation, documented VT/VF, or unexplained cardiac arrest (1). The 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines use ≤ 0.34 second (2). This criterion is met by approximately 5/10,000 persons < 21 years of age (3). Genetic testing has a low yield (approximately 20%) (4). Diagnostic criteria have been proposed (1, 5). Additional testing may include ambulatory cardiac rhythm monitoring and cardiac imaging.

First-degree family members of patients should have clinical evaluation (ie, to detect symptoms suggestive of arrhythmia) and ECG. Genetic testing of family members is done when the patient has an identified mutation.

Diagnosis references

  1. 1. Priori SG, Blomstrom-Lundqvist C, Mazzanati A, et al: 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36:2793–2867, 2015. doi: 10.1093/eurheartj/ehv316

  2. 2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al: 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation138(13):e272–e391, 2018. doi: 10.1161/CIR.0000000000000549

  3. 3.  Guerrier K, Kwiatkowski D, Czosek RJ, et al: Short QT Interval Prevalence and Clinical Outcomes in a Pediatric Population. Circ Arrhythm Electrophysiol 8(6):1460–1464, 2015. doi: 10.1161/CIRCEP.115.003256

  4. 4. Giustetto C, Schimpf R, Mazzanti A, et al: Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 58(6):587–595, 2011. doi: 10.1016/j.jacc.2011.03.038

  5. 5. Gollob MH, Redpath CJ, Roberts JD: The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 57:802–812.2011. doi: 10.1016/j.jacc.2010.09.048

Treatment of Short QT Interval Syndromes

  • Treatment of any VT/VF

  • Usually an implantable cardioverter-defibrillator (ICD)

1). Expert consensus is that an ICD may be considered for asymptomatic patients with a family history of sudden death (1, 2).

Treatment references

  1. 1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al: 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138(13):e272–e391, 2018. doi: 10.1161/CIR.0000000000000549

  2. 2. Priori SG, Wilde AA, Horie M, et al: HRS/EHRA/APHRS Expert Consensus Statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: : document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10:1932–1963, 2013. doi: 10.1016/j.hrthm.2013.05.014

Drugs Mentioned In This Article
quizzes_lightbulb_red
Test your KnowledgeTake a Quiz!
Download the free Merck Manual App iOS ANDROID
Download the free Merck Manual App iOS ANDROID
Download the free Merck Manual App iOS ANDROID